KR20180052755A - 항진균 화합물 및 이의 제조방법 - Google Patents

항진균 화합물 및 이의 제조방법 Download PDF

Info

Publication number
KR20180052755A
KR20180052755A KR1020187010879A KR20187010879A KR20180052755A KR 20180052755 A KR20180052755 A KR 20180052755A KR 1020187010879 A KR1020187010879 A KR 1020187010879A KR 20187010879 A KR20187010879 A KR 20187010879A KR 20180052755 A KR20180052755 A KR 20180052755A
Authority
KR
South Korea
Prior art keywords
solvent
compound
polymorph
mixture
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187010879A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 데일 월스
크리스토퍼 엠. 예이츠
Original Assignee
브이피에스-3, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브이피에스-3, 인크. filed Critical 브이피에스-3, 인크.
Publication of KR20180052755A publication Critical patent/KR20180052755A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/713—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with four or more nitrogen atoms as the only ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0234—Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
    • B01J31/0235—Nitrogen containing compounds
    • B01J31/0244—Nitrogen containing compounds with nitrogen contained as ring member in aromatic compounds or moieties, e.g. pyridine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B53/00—Asymmetric syntheses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B57/00—Separation of optically-active compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B63/00—Purification; Separation; Stabilisation; Use of additives
    • C07B63/02—Purification; Separation; Stabilisation; Use of additives by treatment giving rise to a chemical modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/42—Separation; Purification; Stabilisation; Use of additives
    • C07C303/44—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/30—Addition reactions at carbon centres, i.e. to either C-C or C-X multiple bonds
    • B01J2231/34—Other additions, e.g. Monsanto-type carbonylations, addition to 1,2-C=X or 1,2-C-X triplebonds, additions to 1,4-C=C-C=X or 1,4-C=-C-X triple bonds with X, e.g. O, S, NH/N
    • B01J2231/341—1,2-additions, e.g. aldol or Knoevenagel condensations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Materials Engineering (AREA)
  • Zoology (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020187010879A 2015-09-18 2016-09-16 항진균 화합물 및 이의 제조방법 Ceased KR20180052755A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562220384P 2015-09-18 2015-09-18
US62/220,384 2015-09-18
US201662275504P 2016-01-06 2016-01-06
US62/275,504 2016-01-06
PCT/US2016/052300 WO2017049196A1 (en) 2015-09-18 2016-09-16 Antifungal compounds and processes for making

Publications (1)

Publication Number Publication Date
KR20180052755A true KR20180052755A (ko) 2018-05-18

Family

ID=58289604

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020187010879A Ceased KR20180052755A (ko) 2015-09-18 2016-09-16 항진균 화합물 및 이의 제조방법
KR1020187010880A Active KR102798709B1 (ko) 2015-09-18 2016-09-16 항진균 화합물 제조 방법
KR1020187010867A Ceased KR20180053393A (ko) 2015-09-18 2016-09-16 항진균 화합물 제조 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020187010880A Active KR102798709B1 (ko) 2015-09-18 2016-09-16 항진균 화합물 제조 방법
KR1020187010867A Ceased KR20180053393A (ko) 2015-09-18 2016-09-16 항진균 화합물 제조 방법

Country Status (17)

Country Link
US (4) US10513505B2 (enExample)
EP (3) EP3349586B1 (enExample)
JP (4) JP6887993B2 (enExample)
KR (3) KR20180052755A (enExample)
CN (3) CN108347949B (enExample)
AU (3) AU2016323767B2 (enExample)
BR (2) BR112018005194B1 (enExample)
CA (3) CA2998807A1 (enExample)
EA (3) EA037521B1 (enExample)
ES (2) ES2821021T3 (enExample)
HK (3) HK1258863A1 (enExample)
HU (1) HUE053638T2 (enExample)
MX (3) MX391538B (enExample)
PL (1) PL3349586T3 (enExample)
TW (3) TWI766842B (enExample)
WO (3) WO2017049196A1 (enExample)
ZA (1) ZA201801404B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016021257B1 (pt) 2014-03-19 2021-03-02 Viamet Pharmaceuticals (NC), Inc. 2-(2,4- difluorofenil-1,1-diflúor-1-(5-substituído-piridin-2-il)-3- (1h-tetrazol-1-il)propan-2-óis e processos para preparação e uso dos mesmos
WO2015143142A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
EP3119756B9 (en) * 2014-03-19 2021-08-25 Dow AgroSciences LLC 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation
EP3119771B1 (en) 2014-03-19 2020-05-06 Mycovia Pharmaceuticals, Inc. Antifungal compound process
AU2015231234B2 (en) 2014-03-19 2019-04-04 Mycovia Pharmaceuticals, Inc. Antifungal compound process
CA2942932A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
CA2942231A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
US10399943B2 (en) 2014-03-19 2019-09-03 Mycovia Pharmaceuticals, Inc. Antifungal compound process
AU2015231226B2 (en) 2014-03-19 2019-04-04 Mycovia Pharmaceuticals, Inc. Antifungal compound process
KR20180052755A (ko) 2015-09-18 2018-05-18 브이피에스-3, 인크. 항진균 화합물 및 이의 제조방법
CN109666019B (zh) * 2017-10-14 2021-04-06 朱允涛 一种氘代的氮唑醇类化合物及其制备方法和用途
BR112020009446A2 (pt) 2017-11-13 2020-11-03 Bayer Aktiengesellschaft derivados de tetrazólio propila e seu uso como fungicida
WO2021188404A1 (en) * 2020-03-19 2021-09-23 Assia Chemical Industries Ltd Solid state forms of oteseconazole and process for preparation thereof
CN117915913A (zh) * 2021-07-22 2024-04-19 迈科维亚医药公司 包含奥特康唑的组合物
CN114573503B (zh) * 2022-03-28 2024-04-09 浙江天宇药业股份有限公司 一种制备奥特康唑中间体的方法
CN114573557B (zh) * 2022-03-28 2024-03-08 浙江天宇药业股份有限公司 一种奥特康唑的制备方法
CN116621816B (zh) * 2022-09-23 2025-07-04 北京莱瑞森医药科技有限公司 一种伏立康唑对映异构对b的拆分方法
CN119855811A (zh) * 2022-09-30 2025-04-18 上海济煜医药科技有限公司 双环类化合物的无定形、结晶固体及其制备方法
CN119798219B (zh) * 2025-01-13 2025-07-18 长治医学院 一种奥特康唑的制备方法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2854015B2 (de) 1978-12-14 1980-10-09 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur Herstellung von !H-TetrazoI-1-essigsauren und bestimmter Ester derselben
CS228931B2 (cs) 1981-06-06 1984-05-14 Pfizer Způsob výroby 2-(2,4-difluorfenyl)-l,3-bis(lH-l,2,4-triazol-l-yl)propan- -2-oiu
DE3262386D1 (en) 1981-06-06 1985-03-28 Pfizer Ltd Antifungal agents, processes for their preparation, and pharmaceutical compositions containing them
GB8304282D0 (en) 1983-02-16 1983-03-23 Pfizer Ltd Antifungal agents
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
PT96059B (pt) 1989-12-04 1998-07-31 Searle & Co Sistema de camada unica para a administracao de um medicamento por via transdermica
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
DE69228827T2 (de) 1991-12-18 1999-10-21 Minnesota Mining And Mfg. Co., Saint Paul Mehrschichtige sperrstrukturen
EP0553769B1 (de) 1992-01-29 1996-01-03 FRANZ VÖLKL GmbH & CO. SKI UND TENNIS SPORTARTIKELFABRIK KG Ballspielschläger, insbesondere Tennisschläger
JP2000344744A (ja) 1999-06-04 2000-12-12 Ss Pharmaceut Co Ltd アセトフェノン誘導体およびその製法
CN1565118A (zh) * 2001-10-08 2005-01-12 皇家飞利浦电子股份有限公司 用于运动估计的装置和方法
JP2004359646A (ja) 2003-06-09 2004-12-24 Ss Pharmaceut Co Ltd 抗真菌活性を有する新規アゾール誘導体
US7241800B2 (en) * 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
KR100889937B1 (ko) 2007-08-06 2009-03-20 한미약품 주식회사 보리코나졸의 제조방법
UA108596C2 (xx) 2007-11-09 2015-05-25 Інгібітори пептиддеформілази
KR101109215B1 (ko) 2009-06-17 2012-01-30 보령제약 주식회사 보리코나졸의 신규 중간체 및 이를 이용한 보리코나졸의 제조방법
WO2010146113A1 (en) 2009-06-18 2010-12-23 Basf Se Antifungal 1, 2, 4-triazolyl derivatives having a 5- sulfur substituent
BR112012027308B1 (pt) 2010-04-24 2021-07-06 Mycovia Pharmaceuticals, Inc. compostos inibidores de metaloenzima e composições compreendendo os mesmos
IN2014DN00288A (enExample) 2011-06-19 2015-06-05 Viamet Pharmaceuticals Inc
WO2012177608A1 (en) 2011-06-19 2012-12-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
AU2012273007A1 (en) 2011-06-23 2014-01-30 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
TW201329025A (zh) 2011-11-01 2013-07-16 Astex Therapeutics Ltd 醫藥化合物
US9309273B2 (en) * 2011-12-11 2016-04-12 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
AU2013209516A1 (en) 2012-01-20 2014-08-28 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
US9414596B2 (en) 2012-01-20 2016-08-16 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CA3218491A1 (en) 2012-06-04 2013-12-12 Pharmacyclics Llc Crystalline forms of a bruton's tyrosine kinase inhibitor
KR20140012226A (ko) * 2012-07-18 2014-02-03 엘지전자 주식회사 태양전지 모듈
US20150246898A1 (en) 2012-09-12 2015-09-03 Dow Agrosciences Llc Metalloenzyme inhibitor compounds
US9663488B2 (en) 2013-01-28 2017-05-30 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
WO2014165861A1 (en) 2013-04-05 2014-10-09 The Regents Of The University Of California Metal-catalyzed coupling of aryl and vinyl halides with alpha, alpha-difluorocarbonyl compounds
JP6387401B2 (ja) 2013-05-28 2018-09-05 ヴィアメット ファーマスーティカルズ（エヌシー），インコーポレイテッド 殺真菌組成物
CN105431418B (zh) 2013-06-12 2019-02-05 北卡罗来纳维亚梅特制药公司 金属酶抑制剂化合物
CA2942231A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
AU2015231226B2 (en) * 2014-03-19 2019-04-04 Mycovia Pharmaceuticals, Inc. Antifungal compound process
WO2015143142A1 (en) * 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
AU2015231234B2 (en) 2014-03-19 2019-04-04 Mycovia Pharmaceuticals, Inc. Antifungal compound process
WO2015143137A1 (en) * 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
EP3119756B9 (en) 2014-03-19 2021-08-25 Dow AgroSciences LLC 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation
BR112016021257B1 (pt) 2014-03-19 2021-03-02 Viamet Pharmaceuticals (NC), Inc. 2-(2,4- difluorofenil-1,1-diflúor-1-(5-substituído-piridin-2-il)-3- (1h-tetrazol-1-il)propan-2-óis e processos para preparação e uso dos mesmos
EP3119771B1 (en) 2014-03-19 2020-05-06 Mycovia Pharmaceuticals, Inc. Antifungal compound process
CA2942932A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
US10399943B2 (en) 2014-03-19 2019-09-03 Mycovia Pharmaceuticals, Inc. Antifungal compound process
LT3271347T (lt) 2015-03-19 2022-10-10 Mycovia Pharmaceuticals, Inc. Priešgrybeliniai junginiai ir jų gamybos būdai
AU2016265932B2 (en) 2015-05-18 2020-10-08 Viamet Pharmaceuticals (NC), Inc. Antifungal compounds
KR20180052755A (ko) 2015-09-18 2018-05-18 브이피에스-3, 인크. 항진균 화합물 및 이의 제조방법
JP6987070B2 (ja) 2015-11-17 2021-12-22 コルテバ アグリサイエンス エルエルシー ４−（（６−（２−（２，４−ジフルオロフェニル）−１，１−ジフルオロ−２−オキソエチル）ピリジン−３−イル）オキシ）ベンゾニトリル及び製造方法
WO2017087592A1 (en) 2015-11-17 2017-05-26 Viamet Pharmaceuticals, Inc. 4-((6-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1h-1,2,4-triazol-1-yl)propyl)pyridin-3-yl)oxy)benzonitrile and processes of preparation
TWI679198B (zh) 2015-11-17 2019-12-11 美商陶氏益農有限責任公司 製備４-（（６-（２-（２，４-二氟苯基）-１，１-二氟-２-羥基-３-（１ｈ-１，２，４-三唑-１-基）丙基）吡啶-３-基）氧基）苄腈之方法
KR20180101342A (ko) 2015-11-17 2018-09-12 다우 아그로사이언시즈 엘엘씨 4-((6-(2-(2,4-디플루오로페닐)-1,1-디플루오로-2-히드록시-3-(1h-1,2,4-트리아졸-1-일)프로필)피리딘-3-일)옥시)벤조니트릴 및 제조방법
JP6803923B2 (ja) 2015-12-30 2020-12-23 エヌキューピー １５９８，リミテッド 金属酵素阻害化合物

Also Published As

Publication number Publication date
KR20180100297A (ko) 2018-09-10
CN108347949A (zh) 2018-07-31
BR112018005194A2 (pt) 2018-10-09
US20180258068A1 (en) 2018-09-13
AU2016323782B2 (en) 2020-11-26
US10308632B2 (en) 2019-06-04
WO2017049196A1 (en) 2017-03-23
CN108289457B (zh) 2021-08-06
EA037521B1 (ru) 2021-04-07
TW201718540A (zh) 2017-06-01
AU2016323782A1 (en) 2018-03-22
US20180265492A1 (en) 2018-09-20
AU2016323767B2 (en) 2020-10-15
CA2998807A1 (en) 2017-03-23
MX391538B (es) 2025-03-21
WO2017049096A1 (en) 2017-03-23
US10836740B2 (en) 2020-11-17
BR112018005198A2 (pt) 2018-10-09
MX2018003357A (es) 2018-08-16
US20200024252A1 (en) 2020-01-23
TWI730986B (zh) 2021-06-21
JP2021121606A (ja) 2021-08-26
MX391539B (es) 2025-03-21
JP2018532719A (ja) 2018-11-08
HK1258863A1 (zh) 2019-11-22
HK1257225A1 (en) 2019-10-18
US20190194160A1 (en) 2019-06-27
US10513505B2 (en) 2019-12-24
AU2016324148A1 (en) 2018-03-15
JP2018527367A (ja) 2018-09-20
CA2998808A1 (en) 2017-03-23
KR20180053393A (ko) 2018-05-21
HUE053638T2 (hu) 2021-07-28
CA2998805A1 (en) 2017-03-23
PL3349586T3 (pl) 2021-05-31
AU2016323767A1 (en) 2018-03-15
TW201718497A (zh) 2017-06-01
TWI766842B (zh) 2022-06-11
EP3349586A1 (en) 2018-07-25
ES2821021T3 (es) 2021-04-23
EP3349586B1 (en) 2020-12-02
JP6847458B2 (ja) 2021-03-24
TWI723047B (zh) 2021-04-01
EP3349753A1 (en) 2018-07-25
EP3349587A1 (en) 2018-07-25
CN108348511A (zh) 2018-07-31
EA201890752A1 (ru) 2018-08-31
ZA201801404B (en) 2018-12-19
WO2017049080A1 (en) 2017-03-23
HK1263287A1 (zh) 2020-03-20
EA038214B1 (ru) 2021-07-23
BR112018005194B1 (pt) 2022-11-08
EA201890751A1 (ru) 2018-08-31
EP3349587A4 (en) 2019-04-24
TW201718541A (zh) 2017-06-01
JP2018529687A (ja) 2018-10-11
KR102798709B1 (ko) 2025-04-23
EA036098B1 (ru) 2020-09-28
EP3349753A4 (en) 2019-01-23
CA2998805C (en) 2023-09-26
CN108289457A (zh) 2018-07-17
ES2858314T3 (es) 2021-09-30
MX2018003284A (es) 2018-08-23
EP3349587B1 (en) 2020-07-22
EP3349586A4 (en) 2019-04-17
HK1258862A1 (zh) 2019-11-22
US10464921B2 (en) 2019-11-05
AU2016324148B2 (en) 2020-10-29
EA201890522A1 (ru) 2018-08-31
JP6887993B2 (ja) 2021-06-16
MX2018003280A (es) 2018-08-16
CN108347949B (zh) 2021-08-13

Similar Documents

Publication Publication Date Title
KR20180052755A (ko) 항진균 화합물 및 이의 제조방법
KR102151082B1 (ko) 항진균 화합물 제조방법
KR102603277B1 (ko) 항진균성 화합물 및 이의 제조 방법
KR20160138013A (ko) 항진균 화합물 제조방법
HK1246798A1 (en) Antifungal compounds and processes for making
HK1246798B (en) Antifungal compounds and processes for making
HK1263288A1 (en) Antifungal compound process
HK1234744B (zh) 抗真菌化合物的制备方法
HK1234744A1 (en) Antifungal compound process

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180417

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210903

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230918

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20231122

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230918

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I